Evidence map›Paper›PMID 38482132›Full record

ArticleFrontiers in drug delivery2023

Identification of transport systems involved in eflornithine delivery across the blood-brain barrier.

Christopher P Watson, Gayathri Nair Sekhar, Sarah A Thomas

Open access · diamondAbstract read
In one paragraph

Article in Frontiers in drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Christopher P WatsonKing's College London, Institute of Pharmaceutical Science, Franklin-Wilkins Building, Stamford Street, London, UK.
Gayathri Nair SekharKing's College London, Institute of Pharmaceutical Science, Franklin-Wilkins Building, Stamford Street, London, UK.
Sarah A ThomasKing's College London, Institute of Pharmaceutical Science, Franklin-Wilkins Building, Stamford Street, London, UK.
King's College London · GB

Funding

Wellcome Trust 080268
6 · The paper itself

Abstract

Human African Trypanosomiasis (HAT) is a neglected parasitic disease that continues to persist in sub-Saharan Africa. It is fatal if untreated. The first stage of the disease is associated with the presence of the parasite in the periphery and the second stage with the presence of the parasites in the CNS. The treatment of CNS stage HAT requires the drugs to cross the blood-brain barrier (BBB). Eflornithine is an amino acid analogue that is used to treat second stage HAT gambiense both alone and in combination with nifurtimox. Recent studies have identified that accumulation of eflornithine into the parasites (trypanosomes) involves the amino acid transporter (

Indexed as

amino acidsblood-brain barriereflornithineOCTtransportertrypanosomiasisy+-system

Identifiers

PMID38482132
PMCPMC7615738
OpenAlexW4378086164

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.